Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Alain Ravaud, Ignacio Durán et al.|The Lancet|2017Cited by 1.4k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trialMatthew D. Galsky, Enrique Grande, Maria De Santis et al.|The Lancet|2020Cited by 786
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatmentMario Giuliano, Massimo Cristofanilli, Antonio Giordano et al.|Breast Cancer Research|2011Cited by 224
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trialSandro Pignata, I. L. Ray-Coquard, Domenica Lorusso et al.|The Lancet Oncology|2021Cited by 148
Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast CancerUgo De Giorgi, Massimo Cristofanilli, Michal Mego et al.|Clinical Breast Cancer|2012Cited by 126